NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online pharmacies say, in a sign the U.S. drugmaker is gaining ground on its ...

Jeffrey Segal MD, JD, a medico-legal expert and the founder of Medical Justice, discussed the shifting dynamics of the market for GLP-1 receptor agonist medications in a recent blog, “The Whirlwind ...

People struggling with their body weight experienced joy when new, more effective prescription drug options became the rage ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound ...

Eli Lilly will start studying its obesity products as treatments for alcohol and drug abuse, making it the first major ...

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

Stocks, bonds and the dollar saw small moves, with traders unwilling to make any significant bets as they await key inflation data for clues on whether the Federal Reserve will cut or hold rates next ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according ...

A NEW weight loss jabs dubbed the “King Kong” is set to hit the Irish market as soon as next year. Mounjaro can be used to ...